Gotowa bibliografia na temat „Ci qu shi”

Abstract Background: Gemcitabine-Cisplatin (GP) chemotherapy is the standard first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). Toripalimab, a humanized IgG4K monoclonal antibody specific for PD-1, in combination with GP chemotherapy showed significant improvement in progression-free survival (PFS) as first-line treatment for RM-NPC at the interim analysis of the JUPITER-02 study (NCT03581786), a randomized, placebo-controlled, double-blinded international Phase III trial. Here we report the results of the final PFS analysis and the interim overall survival (OS) analysis. Methods: Patients (n=289) with advanced NPC with no prior chemotherapy in the recurrent or metastatic setting were randomized (1:1) to receive toripalimab 240 mg (n=146) or placebo (n=143) in combination with gemcitabine and cisplatin every 3 weeks (Q3W) for up to 6 cycles, followed by monotherapy with toripalimab or placebo Q3W until disease progression, intolerable toxicity, or completion of 2 years of treatment. Stratification factors were ECOG PS (0 vs. 1) and extent of disease (recurrent vs. primary metastatic) at enrollment. Tumor response was assessed by a blinded independent review committee (BIRC) per RECIST v1.1. The primary endpoint was PFS by BIRC in the intention-to-treat population. Secondary end points included PFS by investigator, OS, objective response rate (ORR), duration of response (DOR) and safety. Results: At the final PFS analysis, the median follow-up time was 22.1 months for the toripalimab arm and 21.4 months for the placebo arm by the cut-off date of June 8, 2021. The toripalimab arm had a significantly longer PFS than the placebo arm as assessed by BIRC: median PFS 21.4 vs. 8.2 months, HR=0.52 (95% CI: 0.37-0.73), two-sided p<0.0001. The 1-year PFS rates were 59.0% vs. 32.9%. The ORR was 78.8% vs. 67.1% (P=0.022) and the median DOR was 18.0 vs. 6.0 months, HR= 0.49 (95% CI: 0.33-0.72). Consistently, PFS as assessed by investigator was also significantly longer in the toripalimab arm than the placebo arm: median PFS 17.3 vs. 8.1 months, HR=0.43 (95% CI: 0.31-0.58), P<0.0001. As of June 8, 2021, the median OS was not reached in either arm, with a trend favoring the toripalimab arm, HR=0.59 (95% CI: 0.37-0.94), P=0.024. The improvements of PFS and OS in the toripalimab arm were observed across key subgroups, including PD-L1 expression subgroups. Notably, dynamic decrease of plasma Epstein-Barr Virus DNA copy number from baseline was associated with favorable response. No new safety signal was identified. The incidence of Grade ≥3 adverse events (AEs) (89.7% vs 90.2%) and fatal AEs (2.7% vs 2.8%) were similar between the two arms; however, investigator-determined immune-related AEs (irAEs) (53.4% vs. 21.7%) and Grade ≥3 irAEs (8.9% vs. 1.4%) were more frequent in the toripalimab arm. Conclusions: The addition of toripalimab to GP chemotherapy as first-line treatment for advanced NPC had a manageable safety profile and provided superior PFS with a favorable trend in overall survival than chemotherapy alone. Citation Format: Hai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, Chaosu Hu, Kunyu Yang, Jiyu Wen, Jingao Li, Yingrui Shi, Feng Jin, Ruilian Xu, Jianji Pan, Shenhong Qu, Ping Li, Chunhong Hu, Yi-Chun Liu, Yi Jiang, Xia He, Hung-Ming Wang, Wan-Teck Lim, Rui-Hua Xu, Coherus Biosciences and Shanghai Junshi Biosciences. Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT226.

Abstract Background: The role of circulating tumor DNA (ctDNA) in monitoring response to immunotherapy in NSCLC is unconfirmed. This is a retrospective analysis of association between longitudinal ctDNA levels and clinical outcomes in 1L TIS (anti-PD-1) + chemo-treated patients (pts) with nonsquamous or squamous NSCLC from RATIONALE-304 (NCT03663205) and 307 (NCT03594747), respectively. Methods: Blood samples were collected at baseline (BL), first response (FR, complete or partial response assessed by investigators), and progressive disease (PD). ctDNA level was tested by OncoScreen Plus520 (Burning Rock) and the variant allele fraction categorized as undetectable (UD)/detectable (D). Paired ctDNA analysis of BL and post-BL (FR or PD) values was by Wilcoxon sign-rank test. Median PFS and OS was calculated by Kaplan-Meier methodology. PD-L1 expression stratified Cox model was used to evaluate the effect of ctDNA on PFS and OS for BL and FR (adjusted with BL ctDNA) in each study. Impact of other BL characteristics was also assessed. Results: Of 217 pts treated with TIS + chemo in RATIONALE-304, 76 (35%) at BL, 40 (18%) at FR, and 30 (14%) at PD had ctDNA results. Of 238 pts treated with TIS + chemo in RATIONALE-307, 80 (34%) at BL, 65 (27%) at FR, and 33 (14%) at PD had ctDNA results. Paired ctDNA analysis showed significantly decreased ctDNA levels from BL to FR (P<0.0001 in 304 and 307); no obvious change was detected from BL to PD in both studies. Pts with UD ctDNA status at FR had notably longer median PFS and OS compared with pts with D ctDNA; no such association was observed using BL ctDNA status in either study (Table). Conclusions: FR ctDNA level is decreased from BL, and seems to correlate with clinical outcomes of 1L TIS in combination with chemotherapy in NSCLC; ctDNA has potential to be a surrogate biomarker for efficacy. This requires further prospective validation. Acknowledgments: This study was sponsored by BeiGene, Ltd. Medical writing support, under the direction of the authors, was provided by Simon Lancaster, BSc, of Ashfield MedComms, an Inizio company, and was funded by BeiGene, Ltd. Table. Analysis summary of ctDNA and PFS/OS by visit Baseline (BL) First response (FR) Study RATIONALE-304 RATIONALE-307 RATIONALE-304 RATIONALE-307 ctDNA UD D UD D UD D UD D n 19 57 8 72 32 8 43 22 mPFS, mo (95% CI)a 9.23(5.75, 9.89) 9.69(7.33, 14.52) NR(4.93, NR) 9.76(7.52, 14.55) 17.31(9.89, NR) 9.20(3.71, 11.99) 20.01(9.82, NR) 9.56(7.39, 13.9) PFS HR (95% CI), UD/D 1.14 (0.61, 2.21) 0.40 (0.09, 1.73) 0.16 (0.05, 0.5) 0.54 (0.24, 1.21) PFS P-valueb 0.6421 0.2205 0.0019 0.1322 mOS, mo (95% CI) NR(9.72, NR) NR(14,23, NR) NR(NR, NR) NR(16.89, NR) NR(NR, NR) 18.78(9.92, NR) NR(NR, NR) NR(12.85, NR) OS HR (95% CI), UD/D 1.04 (0.48, 2.25) NE 0.16 (0.04, 0.69) 0.48 (0.15, 1.51) OS P-valueb 0.9254 NE 0.0147 0.2079 aPrimary endpoint assessed by IRC; bP-values are reported for descriptive purposes only in this exploratory study. Abbreviations: CI, confidence interval; D, detectable ctDNA status; HR, hazard ratio; IRC, independent review committee; mo, months; mOS, median overall survival; mPFS, median progression-free survival; NE, not evaluable; NR, not reached; OS, overall survival; PFS, progression-free survival; UD, undetectable ctDNA status Citation Format: Shun Lu, Jie Wang, Meili Sun, Jun Zhao, Chunhong Hu, Mengzhao Wang, Jianying Zhou, Yong Song, Qinghua Zhou, Jiayuan Zhang, Yang Shi, Ruiqi Huang, Xikun Wu, Wanyu He, Xiaofei Qu, Yun Zhang, Zhirong Shen, Yan Yu. Longitudinal ctDNA levels and clinical outcomes of first-line (1L) tislelizumab (TIS) + chemotherapy (chemo) treatment for advanced non-small cell lung cancer (NSCLC) in the RATIONALE-304 and 307 studies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr LB289.

Background:Lupus nephritis (LN) is one of the most severe complications of systemic lupus erythematosus (SLE). Circular RNAs(circRNAs) can act as competitive endogenous RNAs (ceRNAs) to regulate gene transcription, which is involved in mechanism of many diseases, such as, autoimmunity diseases. However, the role of circRNA in lupus nephritis has been rarely reported.Objectives:In this study, we aim to investigate the clinical value of circRNAs and explore the mechanism of circRNA involvement in the pathogenesis of LN.Methods:Renal tissues from three untreated LN patients and three normal controls (NCs) were used to identify differently expressed circRNAs by RNA sequencing (RNA-seq). Validated assays were used by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Correlation analysis and receiver operating characteristic (ROC) curve were used to reveal the clinical value of selected circRNA, miRNA and mRNA. The interactions between circRNA and miRNA, or miRNA and mRNA were further determined by luciferase reporter assay. The degrees of renal fibrosis between the two groups were compared by Masson-trichome staining and immunohistochemistry staining.Results:159 circRNAs were significantly dysregulated in LN patients compared with NC group. The expression of hsa_circ_0123190 was significantly decreased in renal tissues of patients with LN (p=0.014), as same as the sequencing results. The area under the ROC curve of hsa_circ_0123190 in renal tissues was 0.820. Bio-informatic analysis and luciferase reporter assay illustrated that hsa_circ_0123190 can act as a sponge for hsa-miR-483-3p which was also validated to interact with APLNR mRNA. APLNR mRNA expression was positively related with chronicity index (CI) of LN (R2=0.452,p=0.033). Finally, the factors of renal fibrosis, especially TGF-β (p=0.018), were more pronounced in the LN group.Conclusion:Hsa_circ_0123190 could function as a ceRNA to regulate APLNR expression involved in renal fibrosis by sponging hsa-miR-483-3p in LNReferences:[1]Aljaberi N, Bennett M, Brunner HI, Devarajan P. Proteomic profiling of urine: implications for lupus nephritis. Expert review of proteomics. 2019;16(4):303-13.[2]Zheng ZH, Zhang LJ, Liu WX, Lei YS, Xing GL, Zhang JJ, et al. Predictors of survival in Chinese patients with lupus nephritis. Lupus. 2012;21(10):1049-56.[3]Chen LL. The biogenesis and emerging roles of circular RNAs. Nature reviews Molecular cell biology. 2016;17(4):205-11.[4]Mahmoudi E, Cairns MJ. Circular RNAs are temporospatially regulated throughout development and ageing in the rat. Scientific reports. 2019;9(1):2564.[5]Liang D, Wilusz JE. Short intronic repeat sequences facilitate circular RNA production. Genes & development. 2014;28(20):2233-47.[6]Tan WL, Lim BT, Anene-Nzelu CG, Ackers-Johnson M, Dashi A, See K, et al. A landscape of circular RNA expression in the human heart. Cardiovascular research. 2017;113(3):298-309.[7]Zhao Z, Li X, Jian D, Hao P, Rao L, Li M. Hsa_circ_0054633 in peripheral blood can be used as a diagnostic biomarker of pre-diabetes and type 2 diabetes mellitus. Acta diabetologica. 2017;54(3):237-45.[8]Ouyang Q, Huang Q, Jiang Z, Zhao J, Shi GP, Yang M. Using plasma circRNA_002453 as a novel biomarker in the diagnosis of lupus nephritis. Molecular immunology. 2018;101(undefined):531-8.[9]Luan J, Jiao C, Kong W, Fu J, Qu W, Chen Y, et al. CircHLA-C Plays an Important Role in Lupus Nephritis by Sponging miR-150. Molecular therapy Nucleic acids. 2018;10(undefined):245-53.[10]Kuschnerus K, Straessler ET, Müller MF, Lüscher TF, Landmesser U, Kränkel N. Increased Expression of miR-483-3p Impairs the Vascular Response to Injury in Type 2 Diabetes. Diabetes. 2019;68(2):349-60.[11]Huang Z, Wu L and Chen L. Apelin/APJ system: A novel potential therapy target for kidney disease. Journal of cellular physiology. 2018;233(5): 3892-900.Disclosure of Interests:None declared

Tang Song ci jan shang ci dian [La lírica de las dinastías Tang [618-906] y Song [960-1279] Sluzhou, 1986. 1517 pp. Song shi jian shang ci dian [La poesía de la dinastía Song], Shaghai 1987. 1610 pp. Gu shi jian shang ci dian (La poesía antigua), Pekín, 1988. 1414 pp. Yuan qu jian shang ci dian (La canción de la dinastía Yuan [1279-1368]), Pekín 1988. 1521 pp. R. M. Ch.

碩士
國立中興大學
中國文學系所
101
英文摘要 This dissertation aims to investigate the cross-genre writing of 《Tung-Hsien Ci》 among prose, Fu (poetry) and Qu (poetry). In terms of turning the prose into “Ci (poetry),” it discusses the grand style of Chia-Hsuan Ci, mixed with prose syntaxes. As for the turning from Fu to Qu, this article chooses the Ci of Elegant Cial School in Song Dynasty as a contrast to Tung-Hsien Ci. Although there are differences in terms of the style between the two, both of them are mainly chant. Dealing with the turning of Ci to Qu, taking the Ci of Ming Dynasty and Tung Hsien Ci for example , this essay also explores that whether the writing between Ci and Qu was valuable or not. There were many factors result in the confusion between Ci and Qu, for Ming Dynasty. Writing Ci in Qu was another way, or it would injure the vitality of Ci, which would be worthy of investigating. The second chapter is to investigate the features and value in prose sentence Cis. However, most critics still think that it is unorthodox to writing Ci in prose, and difficult to interpret the gloomy and mildly style of Ci. Even the genius such as Chia-Hsuan has still been blamed. Although Ting-zhuo Chen and Zhou-yi Kuang admire the verve and refining of Chia-Hsuan Ci, they treat him as a special case. They think that no profound scholarship is enough to learn Chia-Hsuan Ci, especially Shih-Chuan Chiang, who is considered to imitate Chia-Hsuan Ci, but only dross. Therefore, I will arrange Chia-Hsuan Ci and Shih-Chuan Chiang’s Ci to the same column in the chapter, and analyse the characteristics and defects of Tung-Hsien Ci from the point of view of writing Ci in prose. The third chapter is to emphasize the technique of Fu by Shih-Chuan Chiang. There are many chanting things Ci and written on paintings Cis in Tung-Hsien Ci, this themes most can show the skill of the poet’s depiction and description. I will compare Tung-Hsien Ci and Mei-Xi, Meng-chuang, Bi-shan’s chanting things Cis, this shows that both Chanting Things, why predecessors slightly better. Predecessors master the soul of Ci, without it, depiction is poor. Shih-Chuan Chiang’s chanting things Cis giving people a frivolous impression, especially he often uses anecdotes and legends as allusions, this is similar to the South Song poets, but Shih-Chuan Chiang use allusions incongruously. Most of the allusions he has used come from history books and unofficial history. This means that he may show off the intent of learning. The fourth chapter pay attention to Shih-Chuan Chiang’s style of writing Ci in Qu. Shih-Chuan Chiang is a drama writer, he is just like Shao-Xin Shi, Xian-Zu Tang and Yu Lee. They write Ci accompanied by Qu style, but I think that industry specializing in surgery. A drama writer writing Ci in Qu causes people to be confused with Ci and Qu. If literature loses its significance, this behavior is putting the cart before the horse. Although, since the Ming Dynasty, there is a tendency that Qu is often merged into Ci in the early Qing Dynasty. After worthies and Yi-zun Zhu drastic reforms, Shih-Chuan Chiang still writes Ci in Qu. This makes me associate to his identity as a drama writer. The fifth chapter will integrate the features of Tung-Hsien Ci , and will induct contribution and missing to the history of literature, looking forward to the fair criticism of Tung-Hsien Ci.